UroGen Pharma (NASDAQ:URGN) Rating Reiterated by Oppenheimer

UroGen Pharma (NASDAQ:URGN)‘s stock had its “outperform” rating reiterated by investment analysts at Oppenheimer in a note issued to investors on Wednesday, Benzinga reports. They presently have a $40.00 price objective on the stock. Oppenheimer’s price objective would suggest a potential upside of 211.53% from the company’s previous close.

Several other equities analysts have also recently commented on URGN. Guggenheim initiated coverage on UroGen Pharma in a report on Thursday, August 22nd. They issued a “buy” rating and a $40.00 price target for the company. EF Hutton Acquisition Co. I raised UroGen Pharma to a “strong-buy” rating in a research report on Monday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of UroGen Pharma in a report on Tuesday. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, UroGen Pharma presently has an average rating of “Buy” and an average target price of $48.38.

UroGen Pharma Stock Up 1.9 %

URGN opened at $12.84 on Wednesday. The stock has a market capitalization of $301.15 million, a price-to-earnings ratio of -3.78 and a beta of 1.11. UroGen Pharma has a 1-year low of $10.60 and a 1-year high of $20.70. The business has a 50 day moving average of $13.48 and a 200-day moving average of $14.36. The company has a current ratio of 8.15, a quick ratio of 7.93 and a debt-to-equity ratio of 3.23.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.09). The business had revenue of $21.85 million for the quarter, compared to the consensus estimate of $23.69 million. As a group, sell-side analysts anticipate that UroGen Pharma will post -3.49 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of URGN. Coastal Bridge Advisors LLC increased its holdings in shares of UroGen Pharma by 4.1% during the second quarter. Coastal Bridge Advisors LLC now owns 38,500 shares of the company’s stock worth $646,000 after buying an additional 1,500 shares in the last quarter. Rice Hall James & Associates LLC grew its position in UroGen Pharma by 3.4% during the 2nd quarter. Rice Hall James & Associates LLC now owns 72,787 shares of the company’s stock worth $1,221,000 after acquiring an additional 2,381 shares during the last quarter. ARK Investment Management LLC increased its holdings in UroGen Pharma by 3.7% during the 2nd quarter. ARK Investment Management LLC now owns 151,781 shares of the company’s stock valued at $2,547,000 after purchasing an additional 5,452 shares in the last quarter. ProShare Advisors LLC bought a new position in UroGen Pharma in the 2nd quarter valued at $199,000. Finally, Rhumbline Advisers raised its position in UroGen Pharma by 37.2% in the 2nd quarter. Rhumbline Advisers now owns 50,477 shares of the company’s stock valued at $847,000 after purchasing an additional 13,681 shares during the last quarter. 91.29% of the stock is currently owned by institutional investors and hedge funds.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.